CEBP Meeting Calendar Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schöllkopf, C.
Right arrow Articles by Melbye, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schöllkopf, C.
Right arrow Articles by Melbye, M.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 1791-1796, July 2005
© 2005 American Association for Cancer Research

Cigarette Smoking and Risk of Non-Hodgkin's Lymphoma—A Population-Based Case-Control Study

Claudia Schöllkopf1, Karin Ekström Smedby2, Henrik Hjalgrim1, Klaus Rostgaard1, Ole Gadeberg5, Göran Roos6, Anna Porwit-MacDonald4, Bengt Glimelius3,7, Hans-Olov Adami2 and Mads Melbye1

1 Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark; 2 Department of Medical Epidemiology and Biostatistics and 3 Department of Pathology and Oncology, Karolinska Institutet; 4 Department of Pathology, Karolinska University Hospital, Stockholm, Sweden; 5 Department of Medicine, Vejle Hospital, Vejle, Denmark; 6 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden; and 7 Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden

Requests for reprints: Claudia Schöllkopf, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark; Phone: 45-3268-3222; Fax: 45-3268-3165. E-mail: CKO{at}SSI.dk


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Background: Epidemiologic evidence of an association between tobacco smoking and non-Hodgkin's lymphoma has been conflicting. This may reflect that non-Hodgkin's lymphoma comprises several distinct disease entities with different etiologies, as some studies have indicated an association between smoking and follicular lymphoma.

Objective: To investigate the association between cigarette smoking and non-Hodgkin's lymphoma risk, overall and by subtype.

Methods: As part of a nationwide Danish-Swedish population-based case-control study, we interviewed 3,055 incident non-Hodgkin's lymphoma patients and 3,187 population controls. All lymphomas were uniformly classified according to the WHO classification. We used unconditional logistic regression to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for the association between cigarette smoking and risk of non-Hodgkin's lymphoma.

Results: Cigarette smoking was not associated with the risk of non-Hodgkin's lymphoma overall (OR, 0.97; 95% CI, 0.87-1.08) nor with the major subgroups such as diffuse large B-cell lymphoma (OR, 0.94; 95% CI, 0.79-1.10), chronic lymphocytic leukemia (OR, 0.86; 95% CI, 0.72-1.02), or follicular lymphoma (OR, 1.03; 95% CI, 0.85-1.24). Female smokers were at a marginally increased risk of follicular lymphoma (OR, 1.41; 95% CI, 1.04-1.92). Men who had ever smoked had a significantly increased risk of T-cell lymphoma (OR, 1.67; 95% CI, 1.11-2.51). No dose-response association with cigarette smoking could be established for any lymphoma subgroup.

Conclusion: We found little evidence of an association between cigarette smoking and non-Hodgkin's lymphoma risk overall. Although increased risks of follicular lymphoma in female smokers and of T-cell lymphoma in male smokers were suggested, no dose-response relationship was observed, leaving limited support for causality.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
A remarkable increase in non-Hodgkin's lymphoma incidence in the latter half of the 20th century, not attributable to changes in known risk factors, sparked an intensive scientific search for unrecognized causes for this group of malignancies. Many studies have focused on the possible role of tobacco smoking, arriving, however, at conflicting results. Thus, whereas some studies have reported smoking to be associated with an increased risk of all types of non-Hodgkin's lymphoma combined (1-3), others have reported no unusual lymphoma risk among smokers (4-14). Various methodologic limitations may explain this inconsistency in results, including assessment of smoking status only at start of follow-up in cohort studies, the use of non-Hodgkin's lymphoma mortality rather than incidence as outcome, limited study sizes, and, possibly, gender-specific variation in the putative association between non-Hodgkin's lymphoma and smoking.

Furthermore, few studies include analyses stratified by non-Hodgkin's lymphoma subtypes and might thereby miss associations recognizing non-Hodgkin's lymphoma as a heterogeneous group of malignancies. Accordingly, in addition to non-Hodgkin's lymphoma subtypes varying in both histologic, molecular, and clinical characteristics as well as in prognosis (15, 16), there is mounting evidence that similar heterogeneity applies to their risk factors (17-21). With respect to smoking, several epidemiologic studies have suggested a positive association with non-Hodgkin's lymphoma subtypes, including B-cell high-grade non-Hodgkin's lymphoma (1, 2). Most consistent, however, associations have been found for follicular non-Hodgkin's lymphoma (22-27). The latter association is biologically particularly interesting because smoking may induce the chromosomal translocation t(14;18) (refs. 28, 29), which is found in 70% to 95% of follicular lymphomas (16).

These observations, consistent with the suspicion of etiologic heterogeneity, emphasize that etiologic studies must take histologic subtypes into consideration. We therefore tested the hypothesis that cigarette smoking increases the risk of certain lymphoma subtypes in a large Danish-Swedish population-based study of 3,055 cases of non-Hodgkin's lymphoma and 3,187 controls.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Study Subjects
Between October 1999 and August 2002, a nationwide population-based case-control study of risk factors for malignant lymphomas was carried out in all of Denmark and Sweden. The Scandinavian Lymphoma Etiology study base encompassed the entire population, ages 18 to 74 years old, living in Denmark from June 1, 2000 to August 30, 2002, and in Sweden from October 1, 1999 to April 15, 2002. In Denmark, the study also included participants in a regional pilot phase beginning on November 1, 1999. Subjects with insufficient knowledge of the Danish or Swedish language, with a history of organ transplantation, HIV infection, or prior hematopoietic malignancy, were excluded from the study.

Cases were all patients with a first, newly diagnosed non-Hodgkin's lymphoma (ICD-10: C82-C85, C88.0, C91.3-5, C91.7), including chronic lymphocytic leukemia/small lymphocytic lymphoma (ICD-10: C91.1), according to the WHO classification (16). Newly diagnosed patients were identified through a rapid case ascertainment system organized for this study, consisting of a network of contact physicians from all departments where malignant lymphomas are diagnosed and treated (in total, 39 departments in Denmark and 118 in Sweden). Continuous collaboration with the six regional cancer registries in Sweden and the Danish National Pathology Registry (with an estimated coverage close to 100 percent; ref. 30) ensured complete reporting through the network. Controls were randomly sampled from the entire Danish and Swedish populations using continuously updated computerized population registers. Thus, a subset of controls was sampled every 6 months during the study period, frequency matched by gender and age (in 10-year intervals) within each country on the expected distribution of cases of non-Hodgkin's lymphoma.

Exposure Information
All study participants completed (in person) a telephone interview including questions on height and weight, education, occupation, smoking habits, medical history, and other possible risk factors for malignant lymphoma. We were unable to blind the interviewers to case or control status, but interviewers were unaware of the specific hypotheses under study and instructed to treat cases and controls strictly the same. Participants were asked whether they had ever smoked tobacco daily for at least 1 year, and, if so, they were inquired about the type of tobacco they had been using (cigarettes/other tobacco products/both cigarettes and other tobacco products), and about current or former smoking habits. Concerning cigarettes, questions were asked about age at initiation, average daily consumption, and age at possible cessation.

Histopathologic Classification
The classification of the tumor material has previously been described in detail (30). Briefly, in Denmark, review of tumor material from cases was done within the Danish Lymphoma Group Registry (LYFO; ref. 31) and involved evaluation by expert hematopathologists. In Sweden, cases were histopathologically evaluated by six specially appointed senior hematopathologists/cytologists. All cases in both countries were classified according to the current WHO classification of hematopoietic and lymphoid tumors (16).

Statistical Analyses
We evaluated the association between cigarette smoking (whether combined with other smoked tobacco products or not) and risk of non-Hodgkin's lymphoma by multiple logistic regression analysis. Cigarette smoking was assessed as never/ever, and ever cigarette smokers were further divided into former and current smokers. Ever smoking was defined as daily cigarette smoking for a minimum of 1 year and former smokers as those who had stopped smoking cigarettes at least 1 year before the interview. To assess a possible dose-response relationship between smoking and lymphoma risk, the data were analyzed by comparing age at initiation (≤14, 15-19, 20+ years), smoking intensity (1-9, 10-19, 20+ cigarettes per day), smoking duration (≤9, 10-29, 30+ years), and estimated lifetime exposure (≤149, 150-299, 300+ cigarette-years) in current smokers versus never smokers, and further, by comparing never smokers with former smokers, classified by time since cessation (1-9, 10-19, 20+ years). Two percent of the study participants (n = 119) were excluded from the analyses because their cigarette smoking exposure could not be uniquely characterized (due to a temporary one-time phrasing of an interview question, which made the distinction of cigarette smokers from smokers of other types of tobacco impossible).

Odds ratios (OR) were first calculated with adjustment for the matching variables (age in 10-year intervals, country, and gender) and then in multivariate analyses, with further adjustment for educational level (≤9, 10-12, 13+ years). The latter additional adjustment only changed a few estimates marginally, and therefore only multivariate estimates are shown. Trend tests were based on continuous measures of exposure as originally reported. Ninety-five percent confidence intervals (95% CI) were based on Wald tests. Effect modification by country, age group, or gender was tested by introducing an interaction term in the multivariate regression model. All significance tests were two sided.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Within the study population and time period, 3,055 patients (81% of all identified incident non-Hodgkin's lymphoma patients) and 3,187 controls (71% of potential controls) gave informed consent to participate in the study. Among eligible patients, early death (n = 279, 7%) was the main reason for nonparticipation, whereas unwillingness was the most common reason among controls (n = 718, 23%). Table 1 shows the characteristics of all 6,242 participants. Fifty-three percent of the controls and 54% of the non-Hodgkin's lymphoma patients reported ever having smoked cigarettes. Of these, 43% of the controls and 41% of the patients were current smokers 1 year before the interview.


View this table:
[in this window]
[in a new window]

  		Table 1. Distribution of non-Hodgkin's lymphoma cases and controls according to gender, country, education level, and smoking status

 
Risk of all types of non-Hodgkin's lymphoma combined was not associated with cigarette smoking in multivariate analyses (Table 2). We found no evidence of heterogeneity between women and men nor between Danish and Swedish participants (data not shown). The risk of non-Hodgkin's lymphoma did not seem to vary between current and former smokers, by age at initiation of smoking, number of cigarettes smoked per day, duration of smoking, cumulative lifetime exposure to cigarette smoking, or by time since cessation among former smokers. Similarly, in subtype-specific analyses, cigarette smoking was not associated with increased risks of chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma (Table 2). An exception from this pattern was a statistically significantly increased risk of T-cell lymphomas among current smokers as compared with never smokers.


View this table:
[in this window]
[in a new window]

  		Table 2. Multivariate ORs and 95% CIs for association between cigarette smoking and risk of non-Hodgkin's lymphoma overall and subtypes

 
We further analyzed the risk of non-Hodgkin's lymphoma subtypes, stratified by gender. In these analyses, currently smoking women were at a statistically significantly increased risk of follicular lymphoma (OR, 1.41; 95% CI, 1.04-1.92) compared with women who had never smoked (Table 3), whereas no such increased risk was observed among currently smoking men. This gender variation was statistically significant (P = 0.03, data not shown) using an interaction term instead of stratification. We found no evidence of any dose-response relationship between smoking and risk of follicular lymphoma (Table 3). Further stratification by age did not reveal any significant variation in risk estimates among the women (results not shown).


View this table:
[in this window]
[in a new window]

  		Table 3. Multivariate ORs and 95% CIs for association between cigarette smoking and risk of follicular lymphoma and risk of T-cell lymphoma, stratified by gender

 
In T-cell lymphoma, we found a statistically increased risk of T-cell lymphoma in ever smokers (OR, 1.38; 95% CI, 1.01-1.88) and in current smokers (OR, 1.55; 95% CI, 1.07-2.25), when men and women were analyzed together (Table 2). However, gender stratification revealed smoking history in men as a risk factor for T-cell lymphoma, independent of the smoking status (ever smoker: OR, 1.67; 95% CI, 1.11-2.51; former smoker: OR, 1.63; 95% CI, 1.03-2.57; current smoker: OR, 1.73; 95% CI, 1.05-2.84). The risk estimates in women were not suggestive of a similar association (ever smoker: OR, 1.04; 95% CI, 0.64-1.70; former smoker: OR, 0.75; 95% CI, 0.39-1.45; current smoker: OR, 1.34; 95% CI, 0.77-2.32). However, the gender-specific estimates were not statistically significantly different using an interaction term (P = 0.35, data not shown). We found no evidence of any dose-response relationship between smoking and risk of T-cell lymphoma (Tables 2 and 3).


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
Based on a uniquely large material of 3,055 non-Hodgkin's lymphoma patients and 3,187 population controls, we found no association between cigarette smoking and the overall risk of non-Hodgkin's lymphoma. This observation is consistent with the majority of previous studies (4-14, 32-39), although not all as some studies have suggested an association between cigarette smoking and non-Hodgkin's lymphoma, especially in heavy smokers (1-3, 23, 40, 41). In our study, cigarette smoking was also not associated with increased risk of any major subtype of B-cell lymphomas, when men and women were analyzed together.

Stratified analyses indicated that smoking might be associated with an increased risk of follicular lymphoma in women and of T-cell lymphomas in men. For T-cell lymphoma, the only other indication of an association with smoking stems from a small scaled Italian study encompassing only eight cases of T-cell lymphoma, and reporting an OR of 25.84 (95% CI, 1.95-342.17) in heavy smokers (42).

An increased risk of follicular lymphoma associated with smoking has previously been suggested. Stagnaro et al. (23) reported ORs of 2.1 (95% CI, 1.4-3.2) and 1.8 (95% CI, 1.1-3.0) for follicular lymphoma among ever smokers of blond and mixed tobacco, respectively, reanalyzing an Italian case-control study from 2001 (27) including 1,450 cases of non-Hodgkin's lymphoma and 1,779 controls. A French case-control study including 180 cases of non-Hodgkin's lymphoma and 360 matched controls observed a more than 3-fold increased risk for follicular lymphoma in current smokers (22), and an American cohort study with 674 cases of non-Hodgkin's lymphoma found a relative risk of 1.9 (95% CI, 1.2-2.9) for follicular lymphoma among former smokers (24). Consistent with our findings, the association between smoking and follicular lymphoma in women has also been reported previously. Parker et al. (26) reported a relative risk of 2.3 (95% CI, 1.0-5.0) for follicular lymphoma in currently smoking women in a cohort study including 200 women with non-Hodgkin's lymphoma. Similarly, in the aforementioned original case-control study (27), Stagnaro et al. reported an increased risk of follicular lymphoma among smokers (OR, 1.8; 95% CI, 1.3-2.7), with women, however, apparently being at particularly high risk (OR, 2.3; 95% CI, 1.4-3.8) as compared with smoking men (OR, 1.3; 95% CI, 0.69-2.3). Further, Morton et al. (25) in an American case-control study with 601 cases of non-Hodgkin's lymphoma observed an increased risk of follicular lymphoma in women with a cumulative lifetime exposure of 34 pack-years or greater (OR, 1.8; 95% CI, 1.1-3.2).

Although the gender variation is not easily explained, other observations support a potential role for smoking in lymphoma development. Specifically, cigarette smoking has been associated with several changes in immune function, such as alterations in T-cell subsets (43) and a decrease in the proportion of circulating natural killer cells (44). Although incompletely understood, immune dysfunction is the most well-established risk factor for malignant lymphoma (45, 46). With respect to follicular lymphoma in particular, the chromosomal translocation t(14;18) can furthermore be detected in the peripheral blood lymphocytes of apparently healthy smokers, with increasing frequency in heavy smokers (28, 29). This particular translocation, which up-regulates the antiapoptotic BCL-2 gene and leads to a prolonged survival and increased chance of clonal expansion of B cells, is present in the malignant cells in the vast majority (70-95%) of follicular lymphomas (16). We did not have access to information on t(14;18) status of the follicular lymphomas included in the present study, but note with interest that one study of male lymphoma patients indicated that an association between cigarette smoking and follicular lymphoma may be more pronounced for t(14;18)-positive non-Hodgkin's lymphoma (OR, 1.7; 95% CI, 0.9-3.3) than for t(14;18)-negative non-Hodgkin's lymphoma (OR, 1.1; 95% CI, 0.7-1.7), albeit the difference was not formally statistically significant (47).

Inherited traits may interact with environmental exposure and influence the individual susceptibility to malignant disease. For cigarette smoking, polymorphisms in the glutathione S-transferase (GST) gene, which encodes for polycyclic aromatic hydrocarbons involved in the metabolism of tobacco carcinogens, have been shown to affect the risk of lung cancer (48, 49). A potential etiologic role of the polymorphism has also been suggested for non-Hodgkin's lymphoma in some studies (50-53). Furthermore, it is noteworthy that GST polymorphisms have been identified as a prognostic factor in pediatric non-Hodgkin's lymphoma (54) and as a risk factor for chronic lymphocytic leukemia (55). The latter association is interesting as several epidemiologic studies have shown that patients with chronic lymphocytic leukemia have an increased risk of smoking-related malignancies such as cancers of the lung, urinary bladder, and larynx (56-58). However, there were no positive associations between smoking and risk of chronic lymphocytic leukemia in our analyses, which is consistent with previous studies (11, 23, 24). We cannot, however, exclude that the observed associations for follicular lymphomas and T-cell lymphomas reflect an even stronger association in genetically predisposed individuals, as discussed for several smoking-related malignancies (59-61).

Although positive findings for follicular lymphoma and T-cell lymphoma were consistent with a priori hypotheses based on the literature and, moreover, were observed in analyses restricted to either Danish or Swedish participants, the possible causal implications should be interpreted cautiously. Specifically, for neither lymphoma subgroup evidence could be established of a dose-response relationship between intensity of cigarette smoking and risk. Despite the relatively large size of our initial subtype groups, the stratification by gender rendered the studied case numbers low. Even more given the large number of comparisons made in our study, it cannot be ruled out that the observed associations with follicular lymphoma and T-cell lymphoma are chance findings.

The strengths of our study lie in its uniquely large size, the population-based design, the rapid case ascertainment of incident cases of non-Hodgkin's lymphoma, and the uniform classification of non-Hodgkin's lymphoma subtypes. One limitation of our study remains, however, that exposure data were based on self-reported smoking habits, with the probability of exposure misclassification. This applies in particular to the assessment of past exposure history and the distinction between current and former smoking status and of lifetime dose. It is likely that this bias would affect cases and controls equally and would lead to an attenuation of any true differences between cases and controls, and thus to underestimation of true effects. Importantly, however, two reviews of studies comparing self-reported data of tobacco smoking to biochemical markers hereof showed a high degree of reliability and accuracy in the classification of ever/never and former/current smokers (62, 63). Misclassification of former/current smoking cases could also have resulted from the fact that a number of non-Hodgkin's lymphoma patients were interviewed more than 1 year after diagnosis. However, supplementary analyses excluding these cases did not change the observed estimates (data not shown).

Another possible bias in our case-control study design could result from differential recollection of smoking data in patients and controls. However, the hypothesis of an association between cigarette smoking and risk of non-Hodgkin's lymphoma or one of its subtypes is not well known, and we therefore consider it unlikely that patients would have underreported their smoking habits.

In conclusion, we found little evidence of an association between cigarette smoking and risk of non-Hodgkin's lymphoma overall. Although our results were compatible with an increased risk of follicular lymphoma in female smokers and of T-cell lymphoma in male smokers, we were unable to show a dose-response relationship, leaving limited support for a causal association.


   Acknowledgments
 
We thank project coordinators Charlotte Appel (Statens Serum Institut) and Leila Nyrén (Karolinska Institutet), as well as Kirsten Ehlers at LYFO. We also thank cytologist Edneia Tani (Karolinska Institutet) and pathologists Måns Åkerman (Lund University Hospital), Åke Öst (Medilab, Stockholm), and Christer Sundström (Akademiska Hospital, Uppsala) for extensive review of tumor material. We are deeply indebted to all of the contact doctors and nurses in Denmark and Sweden who participated in our rapid case ascertainment system.


   Footnotes
 
Grant support: The Danish-Swedish study of the epidemiology of malignant lymphomas has been funded by grants from the NIH (#5 R01 CA69269-02), the Swedish Cancer Society (#02 6661), and Plan Denmark.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/17/05; revised 4/13/05; accepted 4/29/05.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Brown LM, Everett GD, Gibson R, Burmeister LF, Schuman LM, Blair A. Smoking and risk of non-Hodgkin's lymphoma and multiple myeloma. Cancer Causes Control 1992;31:49-55.
  2. Freedman DS, Tolbert PE, Coates R, Brann EA, Kjeldsberg CR. Relation of cigarette smoking to non-Hodgkin's lymphoma among middle-aged men. Am J Epidemiol 1998;1489:833–41.
  3. Linet MS, McLaughlin JK, Hsing AW, et al. Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study. Leuk Res 1992;16:621–4.[CrossRef][Medline]
  4. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976;26051:1525–36.
  5. Adami J, Nyren O, Bergstrom R, et al. Smoking and the risk of leukemia, lymphoma, and multiple myeloma (Sweden). Cancer Causes Control 1998;91:49–56.
  6. Cartwright RA, McKinney PA, O'Brien C, et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res 1988;121:81–8.
  7. Miligi L, Seniori CA, Crosignani P, et al. Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. Am J Ind Med 1999;361:60–9.
  8. Nelson RA, Levine AM, Marks G, Bernstein L. Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin's lymphoma. Br J Cancer 1997;7611:1532–7.
  9. Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995;243:504–14.
  10. Tavani A, Negri E, Franceschi S, Serraino D, La Vecchia C. Smoking habits and non-Hodgkin's lymphoma: a case-control study in northern Italy. Prev Med 1994;234:447–52.
  11. Zahm SH, Weisenburger DD, Holmes FF, Cantor KP, Blair A. Tobacco and non-Hodgkin's lymphoma: combined analysis of three case-control studies (United States). Cancer Causes Control 1997;82:159–66.
  12. Fabbro-Peray P, Daures JP, Rossi JF. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France. Cancer Causes Control 2001;123:201–12.
  13. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;1504:375–89.
  14. Willett EV, Smith AG, Dovey GJ, Morgan GJ, Parker J, Roman E. Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma. Cancer Causes Control 2004;158:771–80.
  15. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification—from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 2000;11 Suppl 1:3–10.[Free Full Text]
  16. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
  17. Frizzera G, Rosai J, Dehner LP, Spector BD, Kersey JH. Lymphoreticular disorders in primary immunodeficiencies: new findings based on an up-to-date histologic classification of 35 cases. Cancer 1980;464:692–9.
  18. Swinnen LJ. Transplant immunosuppression-related malignant lymphomas. Cancer Treat Res 1993;66:95–110.[Medline]
  19. Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients. Clinical and histological features and immunological phenotype. Transplantation 1982;334:347–51.
  20. de The G. The etiology of Burkitt's lymphoma and the history of the shaken dogmas. Blood Cells 1993;193:667–73.
  21. Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Adv Cancer Res 1993;62:179–239.[Medline]
  22. Besson H, Renaudier P, Merrill RM, et al. Smoking and non-Hodgkin's lymphoma: a case-control study in the Rhone-Alpes region of France. Cancer Causes Control 2003;144:381–9.
  23. Stagnaro E, Tumino R, Parodi S, et al. Non-Hodgkin's lymphoma and type of tobacco smoke. Cancer Epidemiol Biomarkers Prev 2004;133:431–7.
  24. Herrinton LJ, Friedman GD. Cigarette smoking and risk of non-Hodgkin's lymphoma subtypes. Cancer Epidemiol Biomarkers Prev 1998;71:25–8.
  25. Morton LM, Holford TR, Leaderer B, et al. Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. Br J Cancer 2003;8911:2087–92.
  26. Parker AS, Cerhan JR, Dick F, et al. Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women. Leuk Lymphoma 2000;37:341–9.[Medline]
  27. Stagnaro E, Ramazzotti V, Crosignani P, et al. Smoking and hematolymphopoietic malignancies. Cancer Causes Control 2001;124:325–34.
  28. Bell DA, Liu Y, Cortopassi GA. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst 1995;873:223–4.
  29. Schuler F, Hirt C, Dolken G. Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biol 2003;133:203–9.
  30. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 2005;973:199–209.
  31. d'Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991;2710:1201–8.
  32. Band PR, Le ND, Fang R, Gallagher R. Identification of occupational cancer risks in British Columbia: a population-based case-control study of 769 cases of non-Hodgkin's lymphoma analyzed by histopathology subtypes. J Occup Environ Med 2004;465:479–89.
  33. Hardell L, Eriksson M, Degerman A. Exposure to phenoxyacetic acids, chlorophenols, or organic solvents in relation to histopathology, stage, and anatomical localization of non-Hodgkin's lymphoma. Cancer Res 1994;549:2386–9.
  34. Hughes AM, Armstrong BK, Vajdic CM, et al. Pigmentary characteristics, sun sensitivity and non-Hodgkin lymphoma. Int J Cancer 2004;1103:429–34.
  35. McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr. Smoking and cancer mortality among U.S. veterans: a 26-year follow-up. Int J Cancer 1995;602:190–3.
  36. Paffenbarger RS Jr, Wing AL, Hyde RT. Characteristics in youth predictive of adult-onset malignant lymphomas, melanomas, and leukemias: brief communication. J Natl Cancer Inst 1978;601:89–92.
  37. Rogot E, Murray JL. Smoking and causes of death among U.S. veterans: 16 years of observation. Public Health Rep 1980;953:213–22.
  38. Franceschi S, Serraino D, Bidoli E, et al. The epidemiology of non-Hodgkin's lymphoma in the north-east of Italy: a hospital-based case-control study. Leuk Res 1989;136:465–72.
  39. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst 1977;583:525–47.
  40. De Stefani E, Fierro L, Barrios E, Ronco A. Tobacco, alcohol, diet and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay. Leuk Res 1998;225:445–52.
  41. Persson B, Fredriksson M, Olsen K, Boeryd B, Axelson O. Some occupational exposures as risk factors for malignant lymphomas. Cancer 1993;725:1773–8.
  42. Talamini R, Polesel J, Montella M, et al. Smoking and non-Hodgkin lymphoma: case-control study in Italy. Int J Cancer 2005;115:606–10.[CrossRef][Medline]
  43. Tollerud DJ, Clark JW, Brown LM, et al. The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians. Am Rev Respir Dis 1989;1396:1446–51.
  44. Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis 1989;1391:194–8.
  45. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;897:1221–7.
  46. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;28513:1736–45.
  47. Schroeder JC, Olshan AF, Dent RB, et al. A case-control study of tobacco use and other non-occupational risk factors for t(14;18) subtypes of non-Hodgkin's lymphoma (United States). Cancer Causes Control 2002;132:159–68.
  48. Alexandrov K, Cascorbi I, Rojas M, Bouvier G, Kriek E, Bartsch H. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 2002;2312:1969–77.
  49. Thier R, Bruning T, Roos PH, et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 2003;2063:149–71.
  50. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;1182:477–81.
  51. Rollinson S, Levene AP, Mensah FK, et al. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 2003;1023:1007–11.
  52. Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, Soucek P. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum Mol Genet 2001;1012:1265–73.
  53. Soucek P, Sarmanova J, Kristensen VN, Apltauerova M, Gut I. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Int Arch Occup Environ Health 2002;75 suppl:S86–92.
  54. Dieckvoss BO, Stanulla M, Schrappe M, et al. Polymorphisms within glutathione S-transferase genes in pediatric non-Hodgkin's lymphoma. Haematologica 2002;877:709–13.
  55. Yuille M, Condie A, Hudson C, et al. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002;9911:4216–8.
  56. Greene MH, Wilson J. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985;68:191–217.
  57. Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001;986:1979–81.
  58. Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004;453:507–13.
  59. Popanda O, Schattenberg T, Phong CT, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004;2512:2433–41.
  60. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002;128:1084–8.[Abstract/Free Full Text]
  61. DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 2004;567:447–74.[CrossRef][Medline]
  62. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 1994;847:1086–93.
  63. Wells AJ, English PB, Posner SF, Wagenknecht LE, Perez-Stable EJ. Misclassification rates for current smokers misclassified as nonsmokers. Am J Public Health 1998;8810:1503–9.



This article has been cited by other articles:


Home page
 J Natl Cancer Inst MonogrHome page
B. C.-H. Chiu, Q. Lan, B. J. Dave, A. Blair, S. H. Zahm, and D. D. Weisenburger
The Utility of t(14;18) in Understanding Risk Factors for Non-Hodgkin Lymphoma
J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 69 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
A. Nieters, S. Rohrmann, N. Becker, J. Linseisen, T. Ruediger, K. Overvad, A. Tjonneland, A. Olsen, N. E. Allen, R. C. Travis, et al.
Smoking and Lymphoma Risk in the European Prospective Investigation into Cancer and Nutrition
Am. J. Epidemiol., May 1, 2008; 167(9): 1081 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. Hjalgrim, K. Ekstrom-Smedby, K. Rostgaard, R.-M. Amini, D. Molin, S. Hamilton-Dutoit, C. Schollkopf, E. T. Chang, E. Ralfkiaer, H.-O. Adami, et al.
Cigarette Smoking and Risk of Hodgkin Lymphoma: A Population-Based Case-Control Study
Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1561 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. T. Chang, K. M. Balter, A. Torrang, K. E. Smedby, M. Melbye, C. Sundstrom, B. Glimelius, and H.-O. Adami
Nutrient Intake and Risk of Non-Hodgkin's Lymphoma
Am. J. Epidemiol., December 15, 2006; 164(12): 1222 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. Ekstrom Smedby, C. M. Lindgren, H. Hjalgrim, K. Humphreys, C. Schollkopf, E. T. Chang, G. Roos, L. P. Ryder, K. I. Falk, J. Palmgren, et al.
Variation in DNA Repair Genes ERCC2, XRCC1, and XRCC3 and Risk of Follicular Lymphoma.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 258 - 265.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schöllkopf, C.
Right arrow Articles by Melbye, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schöllkopf, C.
Right arrow Articles by Melbye, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online